


INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY[®]



Risk and Prevention

February 24-25, 2000
Paris, France

*In Association With the International Society of Chemotherapy,
the European Society of Clinical Microbiology and Infectious Diseases, and
the Centers for Disease Control and Prevention*



Are You Doing All You Can
to Stop Methicillin-Resistant
Staphylococcus aureus
Outbreaks Where They Originate...

The Nares

- *Bactroban* Nasal is indicated for eradication of nasal colonization with methicillin-resistant *S. aureus* (MRSA) in adult patients and healthcare workers as part of a comprehensive infection control program to reduce the risk of infection among high-risk patients during MRSA outbreaks.¹
- In a hospital study, *Bactroban* Nasal contributed to a dramatic reduction in MRSA infections and vancomycin costs during an outbreak.²
- Excellent safety profile¹

Single-use tube
(actual size)



The manufacturer of Bactroban Nasal is Becton Dickinson and Company, a registered trademark of Becton Dickinson and Company. © 2007 Becton Dickinson and Company. All rights reserved.

BACTROBAN® NASAL (mupirocin calcium ointment), 2%
Brief summary. For complete prescribing information, see package insert.

INDICATIONS AND USAGE

Bactroban Nasal is indicated for eradication of nasal colonization with methicillin-resistant *Staphylococcus aureus* in adult patients and health care workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of methicillin-resistant *S. aureus* infection during institutional outbreaks of infections with this pathogen.

NOTE:

- (1) There are insufficient data at this time to establish that this product is safe and effective as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal colonization with *S. aureus*.
- (2) There are insufficient data at this time to recommend use of *Bactroban* Nasal for general prophylaxis of any infection in any patient population.
- (3) Greater than 90% of subjects/patients in clinical trials had eradication of nasal colonization 2 to 4 days after therapy was completed. Approximately 30% recolonization was reported in one domestic study within 4 weeks after completion of therapy. These eradication rates were clinically and statistically superior to those reported in subjects/patients in the vehicle-treated arms of the adequate and well-controlled studies. Those treated with vehicle had eradication rates of 5% to 30% at 2 to 4 days post-therapy with 85% to 100% recolonization within 4 weeks.

CONTRAINDICATIONS

Bactroban Nasal is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

WARNINGS

AVOID CONTACT WITH THE EYES. Application of *Bactroban* Nasal to the eye under testing conditions has caused severe symptoms such as burning and tearing. These symptoms resolved within days to weeks after discontinuation of the ointment.

In the event of a sensitization or severe local irritation from *Bactroban* Nasal, usage should be discontinued.

PRECAUTIONS

General: As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi. (See **DOSE AND ADMINISTRATION** in complete prescribing information.)

Information for Patients: Patients should: apply approximately one-half of the ointment from the single-use tube directly into one nostril and the other half into the other nostril; avoid contact of the medication with the eyes; discard the tube after using; press the sides of the nose together and gently massage after application to spread the ointment throughout the inside of the nostrils; and discontinue using *Bactroban* Nasal and call a health care practitioner if sensitization or severe local irritation occurs.

Drug Interactions: The effect of the concurrent application of intranasal mupirocin calcium and other intranasal products has not been studied. Do not apply mupirocin calcium ointment, 2% concurrently with any other intranasal products.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Long-term studies in animals to evaluate carcinogenic potential of mupirocin calcium have not been conducted. Results of the following studies performed with mupirocin calcium or mupirocin sodium *in vitro* and *in vivo* did not indicate a potential for mutagenicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, *Salmonella* reversion test (Ames), *Escherichia coli* mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice. Reproduction studies were performed in rats with mupirocin administered subcutaneously at doses up to 40 times the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m² basis and revealed no evidence of impaired fertility from mupirocin sodium.

Pregnancy: Teratogenic Effects. Pregnancy Category B.

Reproduction studies have been performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 65 and 130 times, respectively, the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m² basis and revealed no evidence of harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when *Bactroban* Nasal is administered to a nursing woman.

Pediatric Use: Safety in children under the age of 12 years has not been established. (See **CLINICAL PHARMACOLOGY** in complete prescribing information.)

ADVERSE REACTIONS

Clinical Trials: In clinical trials, 210 domestic and 2,130 foreign adult subjects/patients received *Bactroban* Nasal ointment. Less than 1% of domestic or foreign subjects and patients in clinical trials were withdrawn due to adverse events. In domestic clinical trials, 17% (36/210) of adults treated with *Bactroban* Nasal ointment reported adverse events thought to be at least possibly drug-related. The incidence of adverse events that were reported in at least 1% of adults enrolled in domestic clinical trials were as follows: headache, 9%; rhinitis, 6%; respiratory disorder, including upper respiratory tract congestion, 5%; pharyngitis, 4%; taste perversion, 3%; burning/stinging, 2%; cough, 2%; and pruritus, 1%.

The following events thought possibly drug-related were reported in less than 1% of adults enrolled in domestic clinical trials: blepharitis, diarrhea, dry mouth, ear pain, epistaxis, nausea and rash. All adequate and well-controlled clinical trials have been performed using *Bactroban* Nasal ointment, 2% in one arm and the vehicle ointment in the other arm of the study.

OVERDOSAGE

Following single or repeated intranasal applications of *Bactroban* Nasal to adults, no evidence for systemic absorption of mupirocin was obtained.

Manufactured by **DPT Laboratories**, San Antonio, TX 78215. Distributed by **SmithKline Beecham Pharmaceuticals**, Philadelphia, PA 19101.

BRS-BN:L3

ATTEND ON-LINE OR IN PERSON DUAL LICENSURE FOR PRACTICING HEALTH CARE PROFESSIONALS



The five year curriculum program (FYCP) leading to an MD degree is presently available to working adult professionals who cannot attend classes at our campus in Antigua because of work, family or other commitments. Information regarding the FYCP may be accessed via our web site at: <http://www.uhsa.ag/five-year/> and the OLBSLP at: <http://www.uhsa.ag/olbslp/> and OLCLP at <http://www.uhsa.ag/online/>.

The Flexible Medical Curriculum for Professionals (FMCP) allows the participants to attend classes at our campus in Antigua. Information regarding the FMCP may be accessed via our web site at: <http://www.uhsa.ag/pstudent/fmcp> and OLCLP at <http://www.uhsa.ag/online/>.

The hospital attendance during the clinical phase of both programs is mandatory and cannot be fulfilled on-line. Clinical Clerkships can be done at our affiliated teaching hospitals or may be done within students work schedule or arranged with the hospital(s) if currently associated with one. **There is a reason Professionals educate here. Excellent track record for 18 years.**

For further information; contact:

UHSa School of Medicine • Dept. of Continuing Medical Education
Dowhill Campus, Box 510 • St. John's, Antigua • West Indies
Tel: 1-268-460-1391 • Fax: 1-268-460-1477 • E-mail:
fmcp@uhsa.edu.ag • uhsa@candw.ag

PLEASE INDICATE YOUR PROFESSION AND SPECIALTY (IF ANY).


Mothers. Spouses. (maybe) Medical Matrix.

What do they have in common? You place your trust in them. When searching the Internet for credible medical information, you need a resource you can trust. *The Lancet* quotes that "Medical Matrix is the most comprehensive compendium of reliable medical information on the Internet."

MEDICAL MATRIX LLC

<http://www.medmatrix.org>

The largest, peer-reviewed directory to the medical Internet.
Free registration.



© 2014 National Science Foundation

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

CONTENTS

EDITORIAL

"Chance Makes a Football of Man's Life"

JEAN CLAUDE PECHÈRE, MD; DIDIER PITTET, MD, MS

365

REVIEWS

How to Survey Nosocomial Infections

PETRA GASTMEIER, MD; DORIT SOHR, PHD; HEINZ-MICHAEL JUST, MD;
ALFRED NASSAUER, MD; FRANZ DASCHNER, MD; HENNING RÜDEN, MD

366

Scheduled Replacement of Central Venous Catheters Is Not Necessary

JEAN-FRANÇOIS TIMSIT, MD

371

The Clinical and Economic Consequences of Nosocomial Central Venous Catheter-Related Infection: Are Antimicrobial Catheters Useful?

SANJAY SAINT, MD, MPH; DAVID L. VEENSTRA, PhD, PHARMD; BENJAMIN A. LIPSKY, MD

375

Improving Compliance With Hand Hygiene in Hospitals

DIDIER PITTET, MD, MS

381

Control of Antibiotic Use in the Community: The Danish Experience

THOMAS LUND SØRENSEN, MD; DOMINIQUE MONNET, DPHARM, PHD

387

Potential Dissemination of Antibiotic Resistance Genes From Transgenic Plants to Microorganisms

FRANCK BERTOLLA, PHD; ELISABETH KAY, MSc; PASCAL SIMONET, PHD

390

Antibiotic Use in Developing Countries

RAÚL E. ISTÚRIZ, MD, FACP; CLAUDE CARBON, MD, FRCP

394

Methicillin-Resistant *Staphylococcus aureus* in the Community: New Battlefronts, or Are the Battles Lost?

BARRY DAVID COOKSON, MRCP, FRCPATH

398

Toward New Biomaterials

BÉATRICE MONTDARGENT, PHD; DIDIER LETOURNEUR, PHD

404

Reasons for Noncompliance With Infection Control Guidelines

BARRY M. FARR, MD, MSC

411

CORRECTION

403

ABSTRACTS FROM THE RISK AND PREVENTION CONFERENCE

417

MEDICAL NEWS

GINA PUGLIESE, RN, MS; MARTIN S. FAVERO, PHD

425

SHEA NEWS

ANDREAS VOSS, MD, PHD

428

*To view abstracts of these articles,
visit us on the Internet at <http://www.slackinc.com/general/iche>*

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

PUBLISHER: Infection Control and Hospital Epidemiology (ISSN-0899-823X, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (856) 848-1000.

SHEA: 19 Mantua Rd., Mt. Royal, NJ 08061; telephone, 856-423-0087; fax, 856-423-3420; e-mail address, sheahq@talley.com.

COPYRIGHT 2000 The Society for Healthcare Epidemiology of America, Inc., and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Printed in the USA.

SUBSCRIPTIONS: Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-\$110.00; Two years-\$148.00; Three years-\$181.00; Institutional: One year-\$133.00; Two years-\$183.00; Three years-\$233.00. Fellows: \$55.00 per year with proof of training status. Canada: \$20.00 additional each year plus 7% for Canadian Goods & Services tax; Overseas surface, \$150.00 each year; Overseas air mail, \$195.00. Single copies of current issues may be obtained for \$15.00, United States and possessions; \$20.00 all other countries.

INSTRUCTIONS TO AUTHORS: Authors may submit manuscripts prepared in accordance with the 1997 revision of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." The Uniform Requirements has been published in several journals, including *Infect Control Hosp Epidemiol* 1997;18:457-464 and *Ann Intern Med* 1997;126:36-47. A digital version is available on our web site (<http://www.slackinc.com/general/iche/ichehome.htm>). Submit to ICHE Editorial Offices, Vanderbilt University School of Medicine, A-1131 Medical Center North, Nashville, TN 37232-2637, USA. All submissions must be accompanied by copyright form(s) signed by all authors (see January issue or our web site).

REPRINTS: All requests to reprint or use material published herein should be addressed to Karen Lambertson, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Karen Lambertson at (856) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

CHANGE OF ADDRESS: Notice should be sent to the publisher 6 weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Periodicals postage paid at Thorofare, New Jersey 08086-9447 and at additional mailing offices. POSTMASTER: Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents-Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, Laboratory Performance Information Exchange System, and RNDex Top 100.

EDITORIAL OFFICES

Vanderbilt University School of Medicine
A-1131 Medical Center North
Nashville, TN 37232-2637
(615) 343-1095; (615) 343-1882 (FAX)
Email: iche@mcmail.vanderbilt.edu

EDITOR

Michael D. Decker, MD, MPH

MANAGING EDITOR

Susan Cantrell

STATISTICAL EDITOR

Beverly G. Mellen, PhD

SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

SECTION EDITORS**Beyond Infection Control:****The New Hospital Epidemiology**

Bryan P. Simmons, MD

Stephen B. Krichevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

Emerging Infectious Diseases

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

Information Management

John A. Sellick, DO

Buffalo, New York

The International Perspective

Mary D. Nettleman, MD, MS

Richmond, Virginia

Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

SHEA News

Andreas Voss, MD, PhD

Nijmegen, The Netherlands

Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY[®]

EDITORIAL ADVISORY BOARD

- | | |
|--------------------------------------|-------------------------------------|
| Jacques F. Acar, MD | Paris, France |
| J. Wesley Alexander, MD | Cincinnati, Ohio |
| Paul Arnow, MD | Chicago, Illinois |
| Graham A.J. Ayliffe, MD | Birmingham, United Kingdom |
| Neil L. Barg, MD | Yakima, Washington |
| Elizabeth Ann Bolyard, RN, MPH, CIC | Atlanta, Georgia |
| John M. Boyce, MD | Providence, Rhode Island |
| Professor Dr. Ilja Braveny | Munich, Germany |
| Christian Brun-Buisson, MD | Creteil, France |
| Charles Bryan, MD | Columbia, South Carolina |
| Donald E. Craven, MD | Boston, Massachusetts |
| Sue Crow, MSN, RN, CIC | Shreveport, Louisiana |
| Franz Daschner, MD | Freiburg, Germany |
| Leigh G. Donowitz, MD | Charlottesville, Virginia |
| Charles E. Edmiston, Jr., PhD | Milwaukee, Wisconsin |
| Theodore C. Eickhoff, MD | Denver, Colorado |
| Bruce Farber, MD | Manhasset, New York |
| Victoria J. Fraser, MD | St. Louis, Missouri |
| Peter C. Fuchs, MD, PhD | Black Butte, Oregon |
| Richard A. Garibaldi, MD | Farmington, Connecticut |
| Robert Gaynes, MD | Atlanta, Georgia |
| Veivl Greene, PhD, MPH | Beer Sheva, Israel |
| David W. Gregory, MD | Nashville, Tennessee |
| David K. Henderson, MD | Bethesda, Maryland |
| Peter N.R. Heseltine, MD | Los Angeles, California |
| Karen Hoffmann, RN, CIC, MS | Chapel Hill, North Carolina |
| Marguerite McMillan Jackson, RN, PhD | San Diego, California |
| Janine Jagger, MPH, PhD | Charlottesville, Virginia |
| William R. Jarvis, MD | Atlanta, Georgia |
| Douglas S. Kernodle, MD | Nashville, Tennessee |
| Robert H. Latham, MD | Nashville, Tennessee |
| Lewis B. Lefkowitz, MD | Nashville, Tennessee |
| Hsieh-Shong Leu, MD, MSc | Taipei, Taiwan |
| Jack Levy, MD | Brussels, Belgium |
| Victor Lorian, MD | Bronx, New York |
| Dennis G. Maki, MD | Madison, Wisconsin |
| William J. Martone, MD | Bethesda, Maryland |
| Allison McGeer, MD | Toronto, Ontario, Canada |
| John E. McGowan, Jr., MD | Atlanta, Georgia |
| Jonathan L. Meakins, MD, DSc | Montreal, Quebec, Canada |
| Robert R. Muder, MD | Pittsburgh, Pennsylvania |
| Joseph M. Mylotte, MD, CIC | Buffalo, New York |
| Lindsay Nicolle, MD | Winnipeg, Manitoba, Canada |
| Juhani Ojajarvi, MD | Helsinki, Finland |
| Michael T. Osterholm, PhD, MPH | Minneapolis, Minnesota |
| Jan Evans Patterson, MD | San Antonio, Texas |
| Sindy M. Paul, MD | Trenton, New Jersey |
| Michael A. Pfaller, MD | Iowa City, Iowa |
| Samuel Ponce de Leon, MD, MSc | Mexico City, Mexico |
| Isaam Raad, MD | Houston, Texas |
| Manfred L. Rotter, MD, DipBact | Vienna, Austria |
| Theodore Sacks, MD | Jerusalem, Israel |
| William E. Scheckler, MD | Madison, Wisconsin |
| Kent Sepkowitz, MD | New York City, New York |
| Denis Spelman, MD | Prahran Victoria, Australia |
| Michael L. Tapper, MD | New York, New York |
| Clyde Thornsberry, PhD | Brentwood, Tennessee |
| Professor Leonid P. Titov | Minsk, Republic of Belarus |
| Timothy R. Townsend, MD | Millwood, Virginia |
| Antoni Trilla, MD, PhD | Barcelona, Spain |
| Professor Wang Shu-Qun | Beijing, People's Republic of China |
| J. John Weems, Jr., MD | Greenville, South Carolina |
| Robert A. Weinstein, MD | Chicago, Illinois |
| Professor Dr. W. Weuffen | Greifswald, Germany |
| Sergio B. Wey, MD | São Paulo, Brazil |
| Rebecca Wurtz, MD | Evanston, Illinois |

SLACK Incorporated

6900 Grove Road
Thorofare, New Jersey 08086
(856) 848-1000

Vice President/Group Publisher

Richard N. Roash

Publisher

John C. Carter

Editorial Director

Jennifer Kilpatrick

Production Editor

Shirley P. Strunk, ELS

Assistant Editor

Eileen C. Anderer

Editorial Assistant

Christine C. Good

Circulation Manager

Lester J. Robeson, CCCP

Production Director

Christine Malin

Production Coordinator

Joanne Patterson

Publishing Director/ Advertising

Wayne McCourt

Pharmaceutical Group Sales Director

Michael LoPresti

Advertising Sales Representative

Tina Panna

Advertising Sales Coordinator

Jill Campise

Classified/Recruitment Sales Manager

Kathy Huntley

Classified/Recruitment Sales Representative

Stacey Goldberg

Win. Destroy.
**You Can
Declare War.**



Win. Scrub. Win.
**Or You Can
Declare Victory.**

Win.
Arm yourself with PREVACARE* Antimicrobial Hand Gel.
A waterless product that combines persistent antimicrobial activity with skin moisturizers for use between hand washes.

Here's the weapon your facility needs to help win the war against nosocomial infections.

PREVACARE* Antimicrobial Hand Gel is a unique, patented waterless surgical scrub and healthcare personnel handwash that demonstrates persistent antimicrobial activity between uses. PREVACARE* Antimicrobial Hand Gel eliminates 99.99% of pathogenic organisms in 15 seconds or less without water or towels, yet is gentle enough for frequent hand washes.

Declare victory over nosocomial infections with help





The Society for Healthcare Epidemiology of America

2000 SHEA/CDC Training Course in Hospital Epidemiology

Program

The program will be held October 14-17, 2000 at the Cincinnati Marriott at RiverCenter, Covington, Kentucky. Timothy W. Lane, M.D., Julie Gerberding, M.D., and Gina Pugliese, R.N., M.S., will co-chair the program. This program, developed by the Society for Healthcare Epidemiology of America (SHEA), and the Centers for Disease Control and Prevention (CDC), is intended for infectious disease fellows and new hospital epidemiologists. It emphasizes hands-on exercises in which participants work in small groups to detect, investigate, and control epidemiological problems encountered in the hospital setting. These work sessions are supplemented with lectures and seminars covering fundamental aspects of hospital epidemiology and surveillance, epidemic investigation, transmission and control of nosocomial infections, disinfection and sterilization, employee health, isolation systems, regulatory compliance, and quality improvement.

Who Should Attend

You should attend if you are a hospital epidemiologist or an infection control practitioner or if you are looking for a course that will provide you with the most current information concerning infection control practices and epidemiological methods in health care. This fundamental program will provide you with opportunities to find solutions to real situations that will occur in the hospital setting. Intensive problem solving sessions are supplemented with lectures and seminars presented by leading authorities.

Scholarships

Scholarships in the amount of \$1,000 will be awarded to infectious disease fellows for the program to defray the special course fee for fellows of \$400 and expenses incurred in attending the training program.

Interested fellows must submit a letter of no more than one page describing why they would like to have additional training in hospital epidemiology. A letter from the fellow's program director outlining the applicant's qualifications and suitability

for the course also is required. The deadline for receipt of scholarship applications for the course is September 1, 2000. The SHEA Educational Activities Committee will select the scholarship recipients based on review of these letters. Winners will be notified in late September.

Nominations

Please send scholarship applications to:

Timothy W. Lane, M.D.
c/o The Society for Healthcare Epidemiology of America
19 Mantua Road
Mt. Royal, NJ 08061

Fees

Individual Registrants	\$575
Fellows in Infectious Disease	\$400

Credits

The Society for Healthcare Epidemiology of America (SHEA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The Society for Healthcare Epidemiology of America designates this continuing education activity for up to 23 hours in Category 1 of the Physician's Recognition Award of the American Medical Association.

General Course Information

Information regarding the schedule, hotel and travel accommodations, discount airfare, and course fees are available from SHEA (856) 423-7222. Note that application for a scholarship does not constitute enrollment in the program. This must be done separately.

Scholarship Awards provided in part by an educational grant from Pfizer Pharmaceuticals.



Labs • NHO • Pratt • Roerig • Specialty
U.S. Pharmaceuticals Group

ONLY SOURCE for all 12 Guidelines

Includes New HIV and HCV Post-Exposure Prophylaxis

Twelve Guidelines (1984 – Present)

Catheter-Associated Urinary Tract Infections
Handwashing and Environmental Control
HIV and HBV Exposure-Prone Procedures
Tuberculosis
IV Device-Related Infections
HIV Postexposure Prophylaxis

Surgical Site Infection
Isolation Precautions in Hospitals
Pneumonia
Vancomycin Resistance
Infection Control in Healthcare Personnel
Occupational Exposure to Hepatitis C Virus

and Index of SHEA Position Papers
Foreword by Julia S. Garner, RN, MN

All In One Single Volume for only
\$99.00*


Order Today – Call **1-800-552-0076**

International Orders Call 414-884-4532

Mention this ad for 10% discount!

www.ETNAComm.com

*Plus shipping & handling.



All The Facts For Your Immunization Program

Immunizing Healthcare Workers: A Practical Approach


Edited by Gregory A. Poland, MD; William Schaffner, MD; Gina Pugliese, RN, MS
300 pp, Hard Cover, 2000, ISBN 1-55642-450-7, Order # 14507, \$109.00

Immunizing Healthcare Workers: A Practical Approach is the first complete resource for dealing with the immunization of healthcare workers. You can find all of the latest information on successfully and safely implementing or updating your immunization program in this landmark book.

Inside you will find that for each of the vaccine-preventable diseases among workers, there is a discussion of disease risks in the healthcare setting, vaccine recommendations, special administration strategies, safety issues, discussion of unresolved issues, and answers to commonly asked questions. There are also case studies of sample programs in specific settings.

This phenomenal book contains the latest recommendations from the US Public Health Service Advisory Committees, Healthcare Infection Control Practices Advisory Committee (HICPAC), and the Advisory Committee on Immunization Practices (ACIP).

Read how the experts overcame obstacles while setting up immunization programs in their healthcare settings. With over 45 contributors to 32 chapters, **Immunizing Healthcare Workers: A Practical Approach** is an essential source for the latest information necessary to implement an effective immunization program.



Both textbooks are an official publication of
The Society for Healthcare Epidemiology of America (SHEA).

Some Case Study Topics:

- Immunizing Providers and Staff in Physicians' Offices
- Vaccination of Healthcare Workers in Long-Term Care Facilities for the Elderly
- Immunization of Affiliating Students and Contract Home Healthcare Workers
- Immunization Strategies for Home Healthcare Personnel
- Immunization of Workers with Altered Host Defenses
- Vaccinating Unimmunized and Partially Immunized Workers
- Assessing Immunity and Exposures: Using a Computerized Surveillance System
- Managing Information in an Immunization Program
- The Internet: A Quick Guide to Vaccine & Immunization Information

ORDER FORM



Please send me _____ copies of **Immunizing Healthcare Workers: A Practical Approach** (Order# 14507) at **\$109.00** each.

Please send me _____ copies of **A Practical Handbook for Hospital Epidemiologists** (Order # 13020) at **\$65.00** each.

NJ residents add 6% sales tax \$ _____
Handling \$ 4.50
Total \$ _____

Name: _____
Address: _____
City: _____ State: _____ Zip: _____
Phone: _____ Fax: _____
E-mail: _____

Check enclosed (Payable to SLACK Incorporated)

Charge my:   

Account #: _____

Exp. date: _____ Signature _____

Prices are subject to change. Shipping charges may apply.

CODE: 1A448

Also Available

A Practical Handbook for Hospital Epidemiologists

Edited by: Lorean A. Herwaldt, MD and co-edited by Michael D. Decker, MD, MPH
448 pp, Soft Cover, 1998, ISBN 1-55642-302-0,
Order # 13020, \$65.00

A Practical Handbook for Hospital Epidemiologists is the most complete source for practical advice on hospital epidemiology. It is intended to be a pragmatic guide that will assist both beginning and experienced practitioners in establishing and operating a successful hospital epidemiology program. This handbook will supplement the various scientific references already available for this field and will help hospital epidemiologists improve their practices.

Mail order form to:

SLACK Incorporated, Professional Book Division,
6900 Grove Road, Thorofare, NJ 08086-9447

Call: (800) 257-8290 or (856) 848-1000

Fax: (856) 853-5991

E-mail: orders@slackinc.com

World Wide Web Site: <http://www.slackinc.com>

11TH ANNUAL SCIENTIFIC MEETING



Royal York Hotel Toronto, Canada April 1 – 3, 2001

WORKSHOPS

- Antibiotic Management in an Era of Increasing Resistance
- Infection Control in a Non-Hospital Setting: Long-Term Care, Outpatient Services
- Outbreak Investigation: The Problem Solving Approach
- An Evidence-Based Review of Isolation Methods

PLENARY SESSIONS

COST-CUTTING EFFORTS: DO THEY CUT CORNERS AS WELL?

1. Reuse of Single-Use Items: How do We Assess What is Safe?
2. Patient/Staff Ratios: Impact on Nosocomial Infections.
3. Early Discharge: Impact on Outcome.

ANTIBIOTIC RESISTANCE

1. Overview of Resistance in Gram-Positive Bacteria: Mechanisms and Dissemination of Resistance.
2. Use of Antibiotics in Agriculture and its Influence on Resistance in Human Pathogens.
3. Efforts to Control Antibiotic Resistance: What Works?

WHAT'S NEW IN THE ICU?

1. New Devices: How Should the New Technologies be Integrated into ICU Infection Control Programs?
2. What Should be the Approach to Use of Antibiotics in the ICU to Prevent Emergence of Resistance?
3. FUO in the ICU: Role of Nosocomial Sinusitis.

HOW SICK IS SICK? SEVERITY OF ILLNESS SCORING SYSTEMS AND RISK ADJUSTMENT

1. How do You Score a Patient in the Adult ICU? Proposals for a Standard Score Scheme.
2. Risk Adjustment in the Surveillance of Surgical Site Infections: The Cutting Edge.
3. Scoring Systems in the NICU/PICU.

SYMPOSIA

THE LATEST ON INFECTION CONTROL IN PEDIATRICS

1. CDC/NACHRI Pediatric Prevention Network
2. Community-Acquired Infections due to Methicillin – Resistant Staphylococcus Aureus (MRSA)
3. Nosocomial Viral Infections

GENE THERAPY AND INFECTION CONTROL

1. Overview of Gene Therapy
2. Clinical Applications of Gene Therapy
3. Infection Control in Gene Therapy

INFECTION CONTROL IN SPECIALIZED POPULATIONS

1. Infection Control for Patients Infected with the Human Immunodeficiency Virus.
2. Epidemiology and Prevention of Nosocomial Infections in Ophthalmology.
3. Infection Control in Dentistry and Oral Surgery

NOSOCOMIAL INFECTIONS IN NON-ACUTE CARE

1. Infection Control in the Patient with Central Nervous System Dysfunction.
2. Respiratory Infections in Long-Term Care Patients
3. Infection Control in Home Care.

MEET THE CONSULTANT BREAKFASTS

- HIV Post - Exposure Prophylaxis
- Pet Therapy
- Outbreak Investigations
- Methods to Improve Compliance with Handwashing
- Nosocomial Infections Associated with Endoscopy
- Construction/Renovation
- Top 10 Ways to Make Friends, Cut Costs, and Impress Your Hospital Administration

For additional information regarding the SHEA Annual Meeting, please contact:

SHEA Meetings Department
19 Mantua Road
Mt. Royal, NJ 08061
Telephone: (856) 423-7222, ext. 350
Fax: (856) 423-3420

Email: sheamtg@talley.com
Website: www.shea-online.org